

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Zetia (ezetimibe)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zetia (ezetimibe)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zetia (ezetimibe) may be when following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of one preferred high intensity statin, or two statins at the maximally tolerated dose, and did NOT achieve LDL cholesterol goal (AACE 2017);

Preferred high intensity statin: atorvastatin (generic Lipitor) 40mg, atorvastatin (generic Lipitor) 80mg

OR

- II. Individual is statin intolerant based on one of the following:
 - A. Inability to tolerate at least 2 statins, with at least one started at the lowest starting daily dose, demonstrated by intolerable symptoms or clinically significant biomarker changes (NLA 2014); **OR**
 - B. Statin associated rhabdomyolysis after a trial of one statin; **OR**
 - C. Individual has a contraindication[^] for statin therapy including active liver disease, unexplained persistent elevation of hepatic transaminases, or pregnancy;

OR

- III. Individual has homozygous familial sitosterolemia.

[^]Muscle aches are not considered a contraindication to statin therapy.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 12, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract.* 2017;23(Suppl 2):1-87.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
6. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol.* 2016;68:92–125.
7. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. [published online ahead of print November 12, 2013]. *J Am Coll Cardiol.* 2013. doi:10.1016/j.jacc.2013.11.002. Available from: <http://www.sciencedirect.com/science/article/pii/S0735109713060282>. Accessed July 11, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.